Physician profile
David Benjamin Kohn
NPI 1720556178
$6,483.72
in general payments reported to CMS, 2019-2025
30 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $1,618 · 2023: $2,135 · 2024: $1,309 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $613.20 | 2022-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $543.24 | 2022-2025 | Rexulti, Nuedexta |
| Corium, LLC | $414.00 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $380.11 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Axsome Therapeutics, INC. | $355.57 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $276.76 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $250.39 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $231.94 | 2021-2025 | Trintellix |
| Tris Pharma INC | $230.54 | 2022-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.31 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $204.06 | 2021-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $201.57 | 2021-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $177.66 | 2021-2024 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $147.82 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $131.90 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $131.19 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $122.56 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $119.38 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $105.07 | 2022-2025 | Rexulti |
| Neos Therapeutics, LP | $86.04 | 2021-2023 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $68.91 | 2023-2024 | Xelstrym, Secuado |
| Validus Pharmaceuticals LLC | $64.65 | 2023-2024 | Equetro |
| Bioxcel Therapeutics, INC. | $63.11 | 2023 | Igalmi |
| Collegium Pharmaceutical, INC. | $58.94 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $57.88 | 2021-2022 | |
| Eisai INC. | $34.52 | 2021 | |
| Supernus Pharmaceuticals, INC. | $31.22 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $31.18 | 2021-2022 | |
| Owp Pharmaceuticals, INC. | $19.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.